NEUROCRINE BIOSCIENCES INC Form 8-K February 21, 2007

Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of the earliest event reported): February 20, 2007

NEUROCRINE BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware0-2270533-0525145(State or other
jurisdiction of
incorporation or
organization)(Commission File
Number)(IRS Employer
Identification No.)

12790 El Camino Real

92130

(Address of principal executive offices)

(Zip Code)

Registrant s telephone number, including area code: (858) 617-7600

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

TABLE OF CONTENTS

ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

 $\underline{SIGNATURES}$

EXHIBIT 99.1

Table of Contents

ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS.

(b) On February 20, 2007, Neurocrine Biosciences, Inc. announced that Adrian Adams has resigned from the Company s Board of Directors.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

99.1 Press release dated February 20, 2007.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: February 20, 2007 NEUROCRINE BIOSCIENCES, INC.

/s/ Timothy P. Coughlin Timothy P. Coughlin Vice President and Chief Financial Officer

Table of Contents

EXHIBIT INDEX

Exhibit

Number Document Description

99.1 Press release dated February 20, 2007